Theratechnologies' Novel AIDS Drug Filed In US
Executive Summary
Theratechnologies' partner TaiMed Biologics is seeking US approval of its novel antibody treatment for multidrug resistant HIV, ibalizumab, which offers a new therapy avenue for the increasing number of HIV patients who have worked through existing treatment options.
You may also be interested in...
Keeping Track: FDA Approves Novel HIV Treatment, New Dosing Regimen For Opdivo; Another Rare Pediatric Disease Designation For Prometic
The latest drug development news and highlights from our US FDA Performance Tracker.
10 First Approvals To Look Out For In 2018
Another hectic 12 months are anticipated at the US FDA as it is set to give its verdict on no fewer than 40 products in 2018. Here Scrip takes a look at 10 of the more interesting candidates approaching the market for the first time.
Confidence Builds For Theratechnologies' Game-Changing HIV Monoclonal
Approval of a transformational new product for the company could come sooner than expected after 48-week data from its pivotal study support long-term efficacy of its anti-HIV monoclonal antibody in advanced patients.